DEF: InMed Pharma: Annual Meeting, Equity Raise Vote Set

InMed Pharmaceuticals Inc. announces its Annual General and Special Meeting on December 17, 2025, seeking shareholder approval for director elections, auditor reappointment, and a potential equity issuance of 20% or more of common shares.

Summary

• The Annual General and Special Meeting (AGSM) of InMed Pharmaceuticals Inc. will be held virtually on Wednesday, December 17, 2025, at 4:00 p.m. Pacific Standard Time.
• Shareholders will vote on receiving the audited consolidated financial statements for the year ended June 30, 2025, electing five (5) directors, re-appointing CBIZ CPAs P.C. as auditor, and approving the potential issuance of 20% or more of the company's common shares under a Standby Equity Purchase Agreement (SEPA).
• The company has already sold $6,224,732 in Common Shares under the SEPA with YA II PN, Ltd., at an average selling price of $5.15 per Common Share, with $3,775,267 remaining available from the $10 million commitment.
• As of October 22, 2025, 2,804,186 Common Shares of InMed were issued and outstanding.
• Sabby Volatility Warrant Master Fund, Ltd. beneficially owned 9.99% of the company's outstanding common shares as of October 22, 2025.
• The company's executive compensation strategy aims to conserve cash for R&D by targeting cash compensation around the 25th percentile and equity-based compensation around the 50th percentile of industry benchmarks.
• Total compensation for CEO Eric A. Adams was $396,973 in fiscal year 2025, a decrease from $415,400 in 2024.
• Total compensation for COO Michael Woudenberg was $347,123 in fiscal year 2025, a decrease from $349,200 in 2024.
• Total compensation for CFO Netta Jagpal was $303,720 in fiscal year 2025 (appointed February 20, 2024).
• Total audit fees for fiscal year 2025 were $408,000 ($212,000 from CBIZ and $196,000 from Marcum), compared to $372,000 in fiscal year 2024.

Sentiment

Score: 6

Explanation: The filing outlines standard corporate governance matters and a crucial equity financing mechanism for a development-stage biopharmaceutical company. While the SEPA provides necessary capital flexibility, the potential for significant shareholder dilution is a notable concern. The company's commitment to strong governance and a compensation strategy that prioritizes R&D cash conservation are positive aspects.

Positives

• The company is committed to maximizing shareholder attendance by holding a virtual meeting, ensuring equal participation regardless of geographic location.
• The Board of Directors has a strong independent majority, with five out of six current directors identified as independent.
• The roles of Chief Executive Officer and Chair of the Board are separated, with an independent Chair (Andrew Hull) providing enhanced oversight.
• Robust corporate governance policies are in place, including an Insider Trading Policy, Auditor Services Pre-Approval Policy, Corporate Disclosure Policy, Related Person Transaction Approval Policy, Code of Conduct, and Whistle Blower Policy.
• The executive compensation strategy is designed to conserve cash for R&D programs by targeting lower cash compensation (25th percentile) while strongly aligning executive interests with shareholders through significant equity-based compensation (50th percentile).
• The Standby Equity Purchase Agreement (SEPA) provides a reliable source of capital for general corporate purposes, including funding working capital, capital expenditures, operating expenses, and strategic business development opportunities like product research and intellectual property acquisition.

Negatives

• The potential issuance of 20% or more of common shares under the SEPA, if approved, will dilute existing shareholders' proportionate ownership in the company.
• Failure to approve Proposal 4 (SEPA share issuance) could impair the company's working capital and ability to fund critical R&D and business development, potentially leading to less advantageous financing options.
• Total compensation for the CEO and COO decreased in fiscal year 2025 compared to fiscal year 2024, which could reflect financial constraints or performance considerations.
• The company has not adopted formal written policies or targets for diversity, specifically regarding women on the Board or in executive officer positions, despite considering diversity as a factor in selection processes.

Risks

• Shareholder Dilution: The potential issuance of 20% or more of common shares under the SEPA will dilute existing shareholders' proportionate ownership. The exact magnitude of this dilutive effect cannot be conclusively determined due to the variable share price at the time of issuance.
• Financing Risk: If Proposal 4 (SEPA share issuance) is not approved by shareholders, the company's working capital and ability to fund capital expenditures, operating expenses, and business development opportunities, including R&D, may be impaired. This could compel the company to explore alternative financing options that may be less advantageous and potentially more dilutive.
• Market Conditions: Actual sales of Common Shares to Yorkville under the SEPA are dependent on various factors, including market conditions and the trading price of the Common Shares, which are beyond the company's control.
• Executive Compensation Risk Oversight: While the Board is actively involved in strategic risk oversight, it has not formally considered the implications of risks associated with the company's compensation policies and practices, although anti-hedging policies are in place.

Future Outlook

The company intends to gradually increase executive base salaries towards the 25th percentile of industry benchmarks over time. The Standby Equity Purchase Agreement (SEPA) is expected to provide a reliable source of capital for ongoing general corporate purposes, including funding working capital, capital expenditures, operating expenses, and the pursuit of business development opportunities, such as continued product research and intellectual property acquisition. The company acknowledges that it cannot predict the future trading price of its Common Shares or the exact dilutive effect of future SEPA issuances.

Management Comments

• "We remain committed to ensuring that Shareholder meetings encourage Shareholder participation and engagement and to making the Meeting accessible and engaging for all involved." (Regarding the virtual Annual General and Special Meeting)
• "The Board believes that having an independent, non-executive chair increases the independent oversight of the Company and enhances the Boards objective evaluation of the Chief Executive Officer; provides the Chief Executive Officer with an experienced sounding board in the Chair; and provides an independent spokesperson for the Company."
• "The Compensation Committee is currently aiming to target cash compensation (salaries plus bonus) around the 25th percentile and equity-based compensation around the 50th percentile of this benchmark data set. The net effect is to conserve cash for R&D programs based on lower cash compensation of this benchmark while strongly aligning executive interests with those of Shareholders by establishing significant equity-based compensation levels."
• "The Board has determined that the SEPA and our ability to issue the Common Shares thereunder in excess of the SEPA Exchange Cap are in the best interests of the Company and its shareholders because the ability to sell Common Shares to Yorkville provides us with a reliable source of capital for general corporate purposes, which may include, but are not limited to, funding working capital, capital expenditures, operating expenses and the selective pursuit of business development opportunities, including continued product research development or intellectual property acquisition."

Industry Context

Operating within the highly competitive biopharmaceutical industry, the company's compensation strategy reflects the intense competition for experienced executives by balancing competitive packages with cash conservation for research and development. The company benchmarks its compensation against a peer group of US and Canadian public, pre-commercial, and commercial biopharmaceutical companies with specific criteria (under 60 employees, less than $75M in revenues, market capitalization less than $150 million), indicating its position as a relatively small, development-stage biotech firm. The reliance on equity financing mechanisms like the SEPA is a common strategy for such companies to fund operations and R&D without immediate significant cash outflows.

Comparison to Industry Standards

• The company's executive compensation strategy targets cash compensation around the 25th percentile and equity-based compensation around the 50th percentile of a benchmark data set. This benchmark includes US and Canadian public, pre-commercial, and commercial biopharmaceutical companies with under 60 employees, less than $75M in revenues, and market capitalization less than $150 million. This approach is consistent with development-stage biopharmaceutical companies aiming to conserve cash for R&D while aligning executive incentives with long-term shareholder value.
• The corporate governance structure, featuring a majority of independent directors (5 out of 6) and the separation of the CEO and Board Chair roles with an independent Chair, aligns with best practices for publicly traded companies, particularly in the biotech sector where strong oversight is crucial.
• The use of a Standby Equity Purchase Agreement (SEPA) for capital raising is a recognized financing tool in the biotech industry, providing flexible access to capital for companies in development phases, similar to arrangements seen with other small-cap biotechs seeking non-traditional funding sources.

Management Changes

Corporate Governance

Related Party Transactions

• Janet Grove, a former director who resigned on February 10, 2025, was a partner of Norton Rose Fulbright Canada LLP (NRFC).
• NRFC and Norton Rose Fulbright US LLP (NRF) provided legal services to the company totaling $316,977 from July 1, 2024, to February 10, 2025.
• NRF also provided legal services totaling $226,793 during the twelve months ended June 30, 2024.
• These transactions were conducted in the company's normal course of operations and were measured at the agreed-upon exchange amount. No legal services were directly provided by Ms. Grove.

Stakeholder Impact

• Shareholders: Face potential dilution from the proposed SEPA share issuance but gain a clearer path for the company to secure necessary capital for operations and R&D. They also have the opportunity to influence corporate direction through voting on directors and auditors.
• Employees: Benefit from a compensation structure designed to attract and retain talent, including extended health insurance and equity-based awards that align their interests with the company's long-term success. Anti-hedging policies are in place for executive officers and directors.
• Management: Their compensation is tied to performance and long-term company objectives, with potential severance benefits under specific termination or change of control events. The SEPA provides a critical funding tool for their strategic initiatives.
• Creditors/Investors: The SEPA provides a structured mechanism for capital infusion, potentially reducing immediate financing risk, but also signals ongoing funding requirements for the development-stage company.
• Regulatory Bodies: The company demonstrates compliance with SEC and Nasdaq rules through its proxy solicitation, corporate governance disclosures, and the process for seeking approval for the capital raise.

Next Steps

• Shareholders are requested to vote on the election of five directors, the re-appointment of CBIZ CPAs P.C. as auditor, and the approval of the SEPA share issuance at the Annual General and Special Meeting on December 17, 2025.
• The Board will consider the resignation of any director who receives more 'withheld' votes than 'for' votes, in accordance with the Majority Voting Policy.
• The company plans to continue utilizing the SEPA for capital as needed, contingent on shareholder approval for issuances exceeding the Nasdaq cap at less than the minimum price.
• Shareholders intending to present proposals for the 2026 annual general meeting must submit them by June 30, 2026, to be considered for inclusion in the proxy statement.

Key Dates

Recommendation

The filing primarily addresses corporate governance and a proposed equity financing mechanism crucial for a development-stage biopharmaceutical company. While the Standby Equity Purchase Agreement (SEPA) offers a vital capital runway for operations and R&D, the potential for significant dilution (20% or more) for existing shareholders is a material concern. The company's commitment to robust governance and a compensation strategy that conserves cash for R&D are positive indicators. However, the ongoing need for capital and the dilutive nature of the proposed raise suggest a 'hold' position. Investors should await clearer visibility on product development milestones and a defined path to profitability that would justify the dilution risk before considering further investment.

Keywords

InMed Pharmaceuticals, INM, Proxy Statement, Annual General Meeting, Special Meeting, Equity Raise, Standby Equity Purchase Agreement, SEPA, Shareholder Dilution, Corporate Governance, Director Election, Auditor Appointment, Executive Compensation, Biopharmaceutical, R&D Funding, Nasdaq Listing Rules